Literature DB >> 33257834

Semaglutide is safe and efficacious for NASH resolution.

Iain Dickson1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33257834     DOI: 10.1038/s41575-020-00396-z

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Authors:  Philip N Newsome; Kristine Buchholtz; Kenneth Cusi; Martin Linder; Takeshi Okanoue; Vlad Ratziu; Arun J Sanyal; Anne-Sophie Sejling; Stephen A Harrison
Journal:  N Engl J Med       Date:  2020-11-13       Impact factor: 91.245

  1 in total
  1 in total

Review 1.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.